Prostate Cancer Coverage from Every Angle

Christopher Sweeney, MBBS, on Prostate Cancer: IMbassador250 Trial on Atezolizumab and Enzalutamide

Posted: Wednesday, May 6, 2020

Christopher Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses a phase III trial that tested whether combining enzalutamide with atezolizumab, vs enzalutamide alone, could improve outcomes in patients with metastatic castration-resistant prostate cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.